research

Ocular Therapeutix, Inc. (OCUL) Discusses Positive Top Line Results From SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD Transcript

Seeking Alpha

2 min read

0 likes

⚡ Quantum Brief

Ocular Therapeutix announced positive Phase 3 trial results for AXPAXLI (OTX-TKI), a potential first-in-class sustained-release tyrosine kinase inhibitor for wet age-related macular degeneration (AMD). The SOL-1 trial met its primary endpoint, demonstrating non-inferiority in vision gains compared to standard anti-VEGF injections, with 90% of patients requiring no rescue therapy through six months. Executive Chairman Pravin Dugel highlighted AXPAXLI’s potential to reduce treatment burden, offering durable efficacy with a single intravitreal injection, addressing a major unmet need in wet AMD management. Steering Committee Chair Arshad Khanani emphasized the trial’s robust safety profile, with no drug-related serious adverse events, reinforcing its viability as a long-acting alternative to frequent anti-VEGF therapies. Analysts and clinicians on the call underscored the commercial potential, noting AXPAXLI could disrupt the $10B+ wet AMD market if approved, pending further regulatory review and Phase 3 confirmation.

AI Audio Summary

0:00 / 0:00

Click to play

Quantum News · Media Library

Understand this faster with AI

Ask ChatGPT

Research with Perplexity

Explain with Claude

Discuss on Grok

SA Transcripts158.45K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Ocular Therapeutix, Inc. (OCUL) Discusses Positive Top Line Results From SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD February 17, 2026 8:00 AM EST Company Participants William Slattery - Vice President of Investor RelationsPravin Dugel - Executive Chairman, President & CEO Conference Call Participants Arshad Khanani - Sierra Eye AssociatesDarius M. MoshfeghiBiren Amin - Piper Sandler & Co., Research DivisionTara Bancroft - TD Cowen, Research DivisionTazeen Ahmad - BofA Securities, Research Division Presentation Operator Good morning, and welcome to the Ocular Therapeutix SOL-1 Topline Data Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded, and a replay will be made available on the Investor Relations section of the Ocular Therapeutix website. This event will conclude at 9:00 a.m. Eastern. I would now like to turn the call over to Ocular's Vice President of Investor Relations, Bill Slattery, Jr. Please go ahead, Mr. Slattery. William SlatteryVice President of Investor Relations Good morning, everyone, and thank you for joining us today. Earlier this morning, we issued a press release outlining the positive topline results from our SOL-1 Phase III clinical trial of AXPAXLI, also referred to as OTX-TKI in wet AMD. Today's conference call will begin with prepared remarks from Dr. Pravin Dugel, Ocular's Executive Chairman, President and CEO; Dr. Arshad Khanani, Director of Clinical Research at Sierra Eye Associates in Reno, Nevada and Steering Committee Chair for the SOL program; and Dr. Darius Moshfeghi, who was a rescue monitor in the SOL-1 trial and is Chief of the Retina Division, Byers Eye Institute at Stanford University School of Medicine. Following the prepared remarks, Dr. Sanjay Nayak, Ocular's Chief Strategy Officer, will join Dr. Dugel, Dr. Khanani and Dr. Moshfeghi for the question-and-answer session. We refer everyone to this morning's press release for a

Read Original

Source Information

Source: Seeking Alpha

Website: https://seekingalpha.com/feed.xml

Discussion

0 professional contributions

Be the first to add a constructive contribution.